LYTIR

Insider · SEC Form 4 · Director, 10% Owner

ORBIMED ADVISORS LLC

In the 12 months to Nov 8, 2026, on the open market: bought $114.7M of BRVE, ETRA, ADRX and 3 more; sold $60.8M of ELVN, SION. Filed a median of 2 business days after the trade.

Open-market purchases and sales this filer reported on SEC Form 4, by the day traded. Insiders have two business days to file. A sale marked 10b5-1 was made under a plan adopted in advance. How to read these

Insider purchases and sales, by month (last 12 months)Insider purchases: $114.7M in total; Insider sales: $60.8M in total.Jun: Insider sales $57.0MJul: Insider purchases $15.0MJul: Insider sales $3.9MAug: Insider purchases $44.9MSep: Insider purchases $36.1MNov: Insider purchases $18.6MDecJanFebMarAprMayJunJulAugSepOctNov
Insider purchases above the line: $114.7MInsider sales below: $60.8M
Dollar value of open-market purchases and sales reported on SEC Form 4, by the month traded. Sales include pre-arranged 10b5-1 plan sales.
  1. ETRABought: Electra Therapeutics, Inc. Nov 5, 2026 156,091 shares filed Nov 5, 2026 2 transactions filing $1.1M
  2. ETRABought: Electra Therapeutics, Inc. Nov 4, 2026 71,367 shares filed Nov 5, 2026 4 transactions filing $537K
  3. ETRABought: Electra Therapeutics, Inc. Nov 3, 2026 245,113 shares filed Nov 5, 2026 4 transactions filing $1.9M
  4. ASPEBought: Aspen Neuroscience, Inc. Nov 2, 2026 1,000,000 shares filed Nov 4, 2026 3,589,132 shares held indirectly after, as filed filing $15.0M
  5. ADRXBought: ADARx Pharmaceuticals, Inc. Sep 28, 2026 950,000 shares filed Sep 30, 2026 3 transactions filing $16.1M
  6. ETRABought: Electra Therapeutics, Inc. Sep 21, 2026 1,333,333 shares filed Sep 23, 2026 2 transactions filing $20.0M
  7. BLSMBought: BlossomHill Therapeutics, Inc. Aug 10, 2026 625,000 shares filed Aug 12, 2026 2,714,279 shares held indirectly after, as filed filing $10.0M
  8. BRVEBought: Braveheart Bio, Inc. Aug 7, 2026 1,940,000 shares filed Aug 11, 2026 2 transactions filing $34.9M
  9. SCTXBought: Scribe Therapeutics, Inc. Jul 27, 2026 1,000,000 shares filed Jul 29, 2026 1,348,825 shares held indirectly after, as filed filing $15.0M
  10. SIONSold: Sionna Therapeutics, Inc. Jul 7, 2026 85,918 shares filed Jul 9, 2026 2,469,959 shares held indirectly after, as filed 10b5-1 plan filing $3.9M
  11. SIONSold: Sionna Therapeutics, Inc. Jun 30, 2026 115,844 shares filed Jul 2, 2026 2,555,877 shares held indirectly after, as filed 10b5-1 plan filing $5.3M
  12. ELVNSold: Enliven Therapeutics, Inc. Jun 22, 2026 860,123 shares filed Jun 24, 2026 4 transactions filing $39.0M
  13. ELVNSold: Enliven Therapeutics, Inc. Jun 15, 2026 281,408 shares filed Jun 17, 2026 2 transactions filing $12.7M

Source: SEC Form 4 filings. Value is shares × the price reported on the filing; a filing whose price failed Lytir's check against the market price is left out, and a trade that related owners reported on separate forms is counted once. Filings can be late, amended or wrong at the source; see methodology.

Other Form 4 entries

Not counted above: entries this filer reported on Form 4 in the same 12 months that are not open-market purchases or sales. Each entry is one line of a filing.

  • ADRX: conversion (code C), 8 entries, Sep 28, 2026
  • ASPE: conversion (code C), 5 entries, Nov 2, 2026
  • ETRA: conversion (code C), 4 entries, Sep 21, 2026
  • BLSM: conversion (code C), 2 entries, Aug 10, 2026
  • BRVE: conversion (code C), 1 entry, Aug 7, 2026
  • SCTX: conversion (code C), 1 entry, Jul 27, 2026
Code C
A conversion of a derivative security, such as preferred stock or units, into shares.

Source: the same SEC Form 4 filings. The codes are the SEC's own transaction codes; the meanings above are a plain-words reading of the SEC's Form 4 instructions.